SCHEMBL17576889

SCHEMBL17576889

O=C(NCc1cccc2ccccc12)c1nn(CCO)c2c1CN(Cc1c[nH]c3ccccc13)CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PEX14 O75381 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17576658 0.92 PEX14 (0.85) PEX14
SCHEMBL19294119 0.91 PEX14 (0.84) PEX14
SCHEMBL17576654 0.90 PEX14 (0.82) PEX14
SCHEMBL19294083 0.90 PEX14 (0.86) PEX14
SCHEMBL19294069 0.90 PEX14 (0.82) PEX14
SCHEMBL17576890 0.90 PEX14 (1.00) PEX14
SCHEMBL19294076 0.90 PEX14 (0.81) PEX14
SCHEMBL17576846 0.88 PEX14 (1.00) PEX14
SCHEMBL20014948 0.88 PEX14 (0.78) PEX14
SCHEMBL19294078 0.88 PEX14 (0.78) PEX14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186789-A1 PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) 2018-07-05 US disclosed
US-20180186789-A1 PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) 2018-07-05 US disclosed
US-9840504-B2 Pyrazolopyridine derivatives and their use in therapy HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGZENTRUM FUER GESUNDHEIT UN (DE) 2017-12-12 US disclosed
US-9840504-B2 Pyrazolopyridine derivatives and their use in therapy HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGZENTRUM FUER GESUNDHEIT UN (DE) 2017-12-12 US disclosed
US-20170247375-A1 PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2017-08-31 US disclosed
US-20170247375-A1 PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2017-08-31 US disclosed
EP-2993174-A1 Pyrazolopyridine derivatives and their use in therapy Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) 2016-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247375-A1 PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY TPP1, PRDX5, TPMT PEX14 782/4885
US-20180186789-A1 PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY TPP1, PRDX5, TPMT PEX14 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.